Fluconazole Prophylaxis with Augmentin: Not Routinely Indicated

Introduction to Fluconazole Prophylaxis

Routine antifungal prophylaxis with fluconazole is not recommended when taking Augmentin (amoxicillin/clavulanate) for most patients, as antibiotics alone do not constitute sufficient risk for invasive candidiasis requiring prophylaxis, according to the Infectious Diseases Society of America 1, 2

Fluconazole prophylaxis or treatment should only be considered if a patient develops actual fungal infection symptoms or belongs to specific high-risk groups, such as those with compromised immune systems 2, 3

For oropharyngeal candidiasis (oral thrush), fluconazole 100-200 mg daily for 7-14 days is recommended for moderate to severe cases, while mild cases may be treated with topical agents first, such as clotrimazole troches 10 mg 5 times daily for 7-14 days, as suggested by the Infectious Diseases Society of America 2, 3
For urinary tract candidiasis, treatment is not recommended unless the patient belongs to high-risk groups, such as neutropenic patients, very low birth weight infants, or patients undergoing urologic procedures, in which case fluconazole 200 mg daily for 2 weeks may be indicated, according to the Infectious Diseases Society of America 1, 4

Neutropenic patients may require fluconazole 400 mg daily for prophylaxis, while ICU patients with multiple risk factors may require fluconazole 800 mg loading dose, then 400 mg daily, as recommended by the Infectious Diseases Society of America 5
Patients with recurrent infections and ongoing immunosuppression may require fluconazole 100 mg three times weekly for chronic suppression, as suggested by the Infectious Diseases Society of America 2, 3

Fluconazole prophylaxis should not be used routinely for immunocompetent patients, as it promotes resistance without proven benefit, according to the Infectious Diseases Society of America 1
Indwelling catheters should be removed if present, as continuing catheters during treatment significantly reduces cure rates, as recommended by the Infectious Diseases Society of America 2, 4
Monitoring for resistance development, particularly with C. glabrata, is crucial, as it may develop resistance during therapy, according to the Infectious Diseases Society of America 2, 4

The Infectious Diseases Society of America recommends fluconazole as an alternative systemic antifungal for patients not responding to initial therapy, particularly in cases of fluconazole-resistant species 6
The Clinical Infectious Diseases guideline suggests fluconazole 400 mg daily for prophylaxis in high-risk chemotherapy patients, particularly those with neutropenia during induction chemotherapy, and recommends continuing prophylaxis for the duration of neutropenia 7

For patients not responding to fluconazole within 3-5 days, the Clinical Infectious Diseases guideline considers alternative systemic antifungals such as echinocandins or amphotericin B formulations, especially in patients with prior azole exposure 6